Investor's Business Daily on MSN6h
How A Side Effect Has Wiped Out Nearly 73% Of Neurogene's Value In A Week
Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett Syndrome ...
bovnews8h
Why Did Wolfe Research Give Gilead Sciences, Inc. (GILD) Stock Outperform Rating?
On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...
bovnews8h
What’s Causing MannKind Corp (MNKD) Stock’s 48.15% Jump Over the Last Six Months?
On Friday, MannKind Corp (MNKD) stock saw a decline, ending the day at $6.8 which represents a decrease of $-0.22 or -3.13% from the prior close of $7.02. The stock opened at $7.05 and touched a low ...
CVS adds four new board members in deal with Glenview Capital
CVS Health said on Monday it added four new members to its board including hedge fund Glenview Capital's chief executive Larry Robbins as part of a standstill agreement with the activist investor. The ...
CVS Health bulks its board up to 16 members, adds hedge fund CEO
CVS Health has added four new board members, including the CEO of a hedge fund that has been critical of the struggling ...
Business Insider15h
Promising Developments in RegenXBio’s RGX-202 Program Drive Buy Rating
Analyst Mani Foroohar of Leerink Partners maintained a Buy rating on RegenXBio (RGNX – Research Report), boosting the price target to $38.00. Don't Miss our Black Friday Offers: Discover the latest ...
Business Insider20h
Aclaris Therapeutics to sell 35.5M shares at $2.25 in private placement
Leerink Partners and Cantor acted as placement agents in connection with the private placement. Don't Miss our Black Friday Offers: Published first on TheFly – the ultimate source for real-time, ...